PI3K inhibition with alpelisib and idelalisib enhances mIBG uptake in a preclinical neuroblastoma model (EANM 2026) - Sep 29, 2026 - Abstract #EP-0031; "We have previously demonstrated that administration of fimepinostat (CUDC-907), a dual histonedeacetylase and phosphoinositide 3-kinase (PI3K) inhibitor, enhances mIBG uptake both in vitro and in vivo in a NB xenograft mouse model.1 Since fimepinostat lacks regulatory approval, we investigated further clinically approved PI3K inhibitors to extend this strategy toward clinical translation. Both alpelisib and idelalisib significantly enhance [123I]mIBG tumour uptake in a NB xenograft, reinforcing PI3K inhibition as a viable strategy to improve mIBG-based theranostics. Idelalisib demonstrated the more favourable profile with consistent enhancement and low variability at the effective dose. Therapeutic studies combining these PI3K inhibitors with [131I]mIBG are underway to determine whether this ~40% increase in tumour uptake translates into improved treatment efficacy in the same preclinical model, with the aim of supporting future clinical translation."
Preclinical • Neuroblastoma • Solid Tumor • PIK3CA • PIK3CD
|
|
M. El Fakiri 1; R. Mansi 1; L. Bohrmann 1; K. Abid 2; M. Fani 1
|